Increased risk of osteoporosis in patients with myasthenia gravis A population-based cohort study

Neurology

Volumn 83, Issue 12, 2014, Pages 1075-1079

  Yeh, Jiann Horng ^a,c   Chen, Hsuan Ju ^b   Chen, Yen Kung ^a,c   Chiu, Hou Chang ^a,c   Kao, Chia Hung ^b  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; OSTEOPOROSIS; PATIENT RISK; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; AGE; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TAIWAN;

ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 84922242201     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000804     Document Type: Article

References (14)

1. Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 2010;43: 371-379.
2. Statland JM, Ciafaloni E. Myasthenia gravis: five new things. Neurol Clin Pract 2013;3:126-133.
3. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-787.
4. Wakata N, Nemoto H, Sugimoto H, et al. Bone density in myasthenia gravis patients receiving long-term prednisolone therapy. Clin Neurol Neurosurg 2004;106:139-141.
5. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298.
6. Lewis SJ, Smith PE. Osteoporosis prevention in myasthenia gravis: a reminder. Acta Neurol Scand 2001;103:320-322.
7. Pouwels S, de Boer A, Javaid MK, et al. Fracture rate in patients with myasthenia gravis: the general practice research database. Osteoporos Int 2013;24:467-476.
8. Chen YL, Yeh JH, Chiu HC. Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol Scand 2013;127:170-174.
9. Weiss RJ, Wick MC, Ackermann PW, et al. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases-a case-control study with 53,108 patients with fracture. J Rheumatol 2010;37:2247-2250.
10. Lai CC, Wang SH, Chen WS, et al. Increased risk of osteoporotic fractures in patients with systemic sclerosis: a nationwide population-based study. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-204832. [Epub ahead of print].
11. Chiu HC, Vincent A, Newsom-Davis J, et al. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 1987;37:1854-1857.
12. Chiu HC, de Lange GG, Willcox N, et al. Immunoglobulin allotypes in caucasian and Chinese myasthenia gravis: differences from Japanese patients. J Neurol Neurosurg Psychiatry 1988;51:214-217.
13. Samelson EJ, Hannan MT. Epidemiology of osteoporosis. Curr Rheumatol Rep 2006;8:76-83.
14. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62: 1515-1526.